Yd Biopharma Limited (YDES)

$12.50 +4.50 (56.25%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin -7,451.52%
Debt to Equity Ratio 0.92
Volume 916,200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Industry: Biotechnology
Sector: Healthcare
Address:
No. 3, Xingnan St., 12F. Nangang Dist., Taipei, Taiwan
_www_larval_com_
_www_larval_com_ Dec. 9 at 8:57 PM
$YDES 6%[-14%] $SWIM 4%[-5%] $LUNG -3%[14%] most notable movement into the final minutes of trading.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 3 at 4:22 PM
$YDES
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Nov. 28 at 4:54 PM
$YDES $11.96 for a high thus far today.
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Nov. 24 at 7:46 PM
$YDES $9.84 for a high. O.k.
0 · Reply
topstockalerts
topstockalerts Nov. 24 at 6:29 PM
YD Bio shares rose after the company announced key regulatory milestones enabling U.S. commercialization of its eye-care products. Its partner 3D Global Biotech received FDA 510(k) clearance for Exovisse contact lenses as a Class II device, while Exovisse artificial tears were developed in compliance with FDA OTC Monograph M018, allowing nationwide over-the-counter distribution. The company also reported that its limbal stem cells and stem-cell–derived exosomes were added to the FDA Drug Master File, providing regulatory support for future therapeutic development. CEO Dr. Ethan Shen said the achievements mark YD Bio’s shift from lab innovation to patient-ready products. YD Bio is planning a small dry-eye clinical trial in Taiwan with YC Biotech and is advancing exosome-based therapeutics with 3D Global Biotech for potential retinal and macular disease treatments. $YDES
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 5:57 PM
YD Bio Stock Rises On Entry Into US Eye Care Segment $YDES $ONEQ https://stocktwits.com/news/equity/markets/yd-bio-stock-rises-on-entry-into-us-eye-care-segment/cL5bivkREQr
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Nov. 23 at 5:00 AM
$YDES On watch for Monday. Current after-hours price is $8.50:
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 16 at 3:47 PM
$YDES YD Bio Limited (YDES) became a Nasdaq-listed biotech after completing a major merger and securing $13.2M in PIPE financing. With DNA methylation cancer detection for pancreatic and breast cancer and exosome-based eye therapies in development, investors are asking whether YDES is positioned for massive growth in 2026 and beyond. https://biotechhealthx.com/biotech-news/yd-bio-ydes-surges-after-13-2m-financing/
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:06 AM
$YDES keep watch if this holds above 11.55
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 8:53 PM
$YDES following closely
0 · Reply
Latest News on YDES
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Dec 9, 2025, 9:00 AM EST - 4 days ago

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Dec 2, 2025, 9:00 AM EST - 11 days ago

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Nov 24, 2025, 9:00 AM EST - 19 days ago

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

Nov 5, 2025, 8:30 AM EST - 5 weeks ago

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Oct 20, 2025, 10:20 AM EDT - 7 weeks ago

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Oct 10, 2025, 8:37 AM EDT - 2 months ago

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

Sep 30, 2025, 5:25 PM EDT - 2 months ago

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

Aug 29, 2025, 7:30 AM EDT - 3 months ago

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

_www_larval_com_
_www_larval_com_ Dec. 9 at 8:57 PM
$YDES 6%[-14%] $SWIM 4%[-5%] $LUNG -3%[14%] most notable movement into the final minutes of trading.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 3 at 4:22 PM
$YDES
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Nov. 28 at 4:54 PM
$YDES $11.96 for a high thus far today.
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Nov. 24 at 7:46 PM
$YDES $9.84 for a high. O.k.
0 · Reply
topstockalerts
topstockalerts Nov. 24 at 6:29 PM
YD Bio shares rose after the company announced key regulatory milestones enabling U.S. commercialization of its eye-care products. Its partner 3D Global Biotech received FDA 510(k) clearance for Exovisse contact lenses as a Class II device, while Exovisse artificial tears were developed in compliance with FDA OTC Monograph M018, allowing nationwide over-the-counter distribution. The company also reported that its limbal stem cells and stem-cell–derived exosomes were added to the FDA Drug Master File, providing regulatory support for future therapeutic development. CEO Dr. Ethan Shen said the achievements mark YD Bio’s shift from lab innovation to patient-ready products. YD Bio is planning a small dry-eye clinical trial in Taiwan with YC Biotech and is advancing exosome-based therapeutics with 3D Global Biotech for potential retinal and macular disease treatments. $YDES
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 5:57 PM
YD Bio Stock Rises On Entry Into US Eye Care Segment $YDES $ONEQ https://stocktwits.com/news/equity/markets/yd-bio-stock-rises-on-entry-into-us-eye-care-segment/cL5bivkREQr
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Nov. 23 at 5:00 AM
$YDES On watch for Monday. Current after-hours price is $8.50:
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 16 at 3:47 PM
$YDES YD Bio Limited (YDES) became a Nasdaq-listed biotech after completing a major merger and securing $13.2M in PIPE financing. With DNA methylation cancer detection for pancreatic and breast cancer and exosome-based eye therapies in development, investors are asking whether YDES is positioned for massive growth in 2026 and beyond. https://biotechhealthx.com/biotech-news/yd-bio-ydes-surges-after-13-2m-financing/
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:06 AM
$YDES keep watch if this holds above 11.55
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 8:53 PM
$YDES following closely
0 · Reply
RumpusBio
RumpusBio Nov. 13 at 3:00 AM
$YDES just getting into this field. I think this is a jewel. What else is out there with bio? Galleri test is legit via Illumina. What else is out there? Instill Bio going ok?. Colossal has a f’n wooly mammoth project! Dallas seems like a hot bed.
0 · Reply
Badbeat72
Badbeat72 Oct. 30 at 3:06 PM
$YDES Timber! Here we go..........about time........
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 28 at 3:16 PM
$YDES Current Stock Price: $16.40 No options data available.
0 · Reply
frankyboyz
frankyboyz Oct. 23 at 7:59 PM
$VTYX Have $FUSE.X on watchlist, it has my "FULL" attention, had it all day. Just my 2c. SPAC ticker change after biz combination… last one I played was $YDES, went from 5 → 25’s. A crazy 500% move, not saying FUSE will or can do same... but hey... sometimes history repeats. Now $FUSE.X has my eyes not only because of that YDES past move, but also today’s 6 → almost 10 run by $SEV, another recent uplister. So yeah… FUSE has it all: SPAC, biz combo, uplist setup (a mix of YDES and SEV ). I’ll eat the dips or slap a potential vol breakout. "Could end up being nothing" you know it... your risk, your call... do your own DD and charting. But as we say in Italy... “It never happens… but if it does…” then I’m looking at 2.75/3.15/3.50/4.50/5/7.30/12+ YOU DO YOU.
0 · Reply
TheFlyingSaucer
TheFlyingSaucer Oct. 21 at 2:57 AM
$YDES warrants will be called soon if we continue to close over $18 for another few days.
1 · Reply
TraderJay85
TraderJay85 Oct. 20 at 10:21 PM
Got the team in early! Made huge gains even with the web outage restricting us. We had over 20 poppers. Here are just a few. $USAR went to 32.25 🔥 $GNLX went to 6.51 🔥 $BTQ went to 12.90 🔥 $YDES went to 22.00 🔥 $BNAI went to .53 🔥
0 · Reply
dividendmaker
dividendmaker Oct. 16 at 2:53 PM
$YDES what’s the deal with warrants here?
1 · Reply
Slangus
Slangus Oct. 9 at 6:20 PM
$YDES why are the warrants so cheap and when will they become exercisable?
0 · Reply
Slangus
Slangus Oct. 9 at 4:51 PM
$YDES i believe i have a bunch of warrants. How much are they to execute and how do I do it?
2 · Reply
StockScanners
StockScanners Sep. 30 at 1:25 AM
$YDES reached 18.40
0 · Reply
TraderJay85
TraderJay85 Sep. 29 at 8:25 PM
$YDES I told you. this is like the 6th one on the day. If you are not hitting at least 3 runners a day, then you aint doin something right. hit the follow and lets win together. if you are at all confused about how to play this one, please reach out.I will explain it so you don't have to miss out on the big run. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER
0 · Reply
TraderJay85
TraderJay85 Sep. 29 at 1:36 PM
$AQB $FOFO $YDES $AUID What an insane run. this one has provided. 68 high. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
0 · Reply